The graft-versus-leukemia effects of allogeneic cell therapy

Annual Review of Medicine

Volumn 50, Issue , 1999, Pages 369-386

  Porter, David L ^a   Antin, Joseph H ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Donor leukocyte infusions; Graft versus host disease (GVHD)

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; EFFECTOR CELL; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; PRIORITY JOURNAL; RELAPSE; REVIEW;

ANTIGENS, NEOPLASM; BONE MARROW TRANSPLANTATION; GRAFT VS TUMOR EFFECT; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; LEUKOCYTE TRANSFUSION; LYMPHOMA; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RETREATMENT; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TUMOR VIRUS INFECTIONS;

EID: 0033011097     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.50.1.369     Document Type: Review

References (81)

1. 1. Clift RA, Buckner CD, Appelbaum FR, et al. 1990. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76: 1867-71
2. 2. Barnes D, Loutit J. 1957. Treatment of murine leukaemia with X-rays and homologous bone marrow. Br. J. Haematol. 3:241-52
3. 3. Slavin S, Or R, Kapelushnik Y, et al. 1992. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 6:164-66
4. 4. Sykes M, Harty M, Szot G, et al. 1994. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4-and CD8-mediated graft-versus-leukemia effects. Blood 83:2560-69
5. 5. Truitt R, Atasoylu A. 1991. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transpl. 8:51-58
6. 6. Truitt R, Johnson B, McCabe C, Weiler M. 1997. Craft Versus Leukemia. New York: Dekker
7. 7. Korngold R, Sprent J. 1987. T cell subsets and graft-versus-host disease. Transplant 44:335-39
8. 8. Truitt R, Shih C, Lefever A, et al. 1983. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-leukemia activity in vivo. J. Immunol. 131:2050-2058
9. 9. Truitt R, LeFever A, Shih C-Y. 1987. Graft-versus-leukemia reactions: experimental models and clinical trails. In Progress in Bone Marrow Transplantation, ed. R Gale, R Champlin, pp. 219-32. New York: Liss
10. 10. Sykes M, Romick M, Sachs D. 1990. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc. Natl. Acad. Sci USA. 87:5633-37
11. 11. OKunewick J, Kochiban D, Machen L, Buffo M. 1994. Comparison of the effects of CD3 and CD5 donor T cell depletion on graft-versus-leukemia in a murine model for MHC-matched unrelated donor-transplantation. Bone Marrow Transpl. 13:11-18
12. 12. Weiss L, Weigensberg M, Morecki S, et al. 1990. Characterization of effector cells of graft-vs-leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol. Immunother. 31:236-42
13. 13. Collins R, Rogers Z, Bennett M, et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transpl. 10:391-95
14. 14. Higano C, Brixey M, Bryant E, et al. 1990. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 50:175-77
15. 15. Odom L, August C, Githens J, et al. 1978. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? Lancet 2:537-40
16. 16. Horowitz M, Gale R, Sondel P, et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-62
17. 17. Gale R, Horowitz M, Ash R, et al. 1994. Identical-twin bone marrow transplants for leukemia. Ann. Int. Med. 120:646-52
18. 18. Apperley J, Mauro F, Goldman J, et al. 1988. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J. Haematol. 69:239-45
19. 19. Kolb H, Mittermuller J, Clemm C, et al. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-65
20. 20. Porter D, Roth M, McGarigle C, et al. 1994. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 330:100-6
21. 21. Drobyski W, Keever C, Roth M, et al. 1993. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82:2310-18
22. 22. van Rhee F, Lin F, Cullis J, et al. 1994. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377-83
23. 23. Hertenstein B, Wiesneth M, Novotny J, et al. 1993. Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplant 56:1114-18
24. 24. Helg C, Roux E, Beris P, et al. 1993. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transpl. 12:125-29
25. 25. Bar B, Schattenberg A, Mensink E, et al. 1993. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol. 11:513-19
26. 26. Collins R, Shpilberg O, Drobyski W, et al. 1997. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:433-44
27. 27. Kolb H, Schattenberg A, Goldman J, et al. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-50
28. 28. Roth M, Antin J, Bingham E, Ginsberg D. 1989. Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood 74:882-85
29. 29. Kolb H, Mittermuller J, Hertenstein H, et al. Adoptive immunotherapy in human and canine chimeras - the role of interferon alpha. Sem. Hematol. 30:37-39
30. 30. Slavin S, Naparstek E, Nagler A, et al. 1996. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195-2204
31. 31. Falkenburg J, Wafelman A, van Bergen C, et al. 1997. Leukemia-reactive cytotoxic T lymphocytes (CTL) induce complete remission in a patient with refractory accelerated phase chronic myeloid leukemia (CML). Blood 90:589a
32. 32. van Besien K, de Lima M, Giralt S, et al. 1997. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transpl. 19:977-82
33. 33. Porter D, Collins R, Mick R, et al. 1997. Unrelated donor leukocyte infusions (DLI) to treat relapse or EBV-lymphoproliferative disease (EBV-LPD) after unrelated donor bone marrow transplantation (BMT). Blood 90:590a
34. 34. Antin J, Ferrara J. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964-68
35. 35. Porter D, Antin J. 1997. Adoptive immunotherapy in bone marrow transplantation. In Graft-versus-Host Disease, ed. S Burakoff, H Deeg, J Ferrara, pp. 733-54. New York: Dekker
36. 36. Anderson K, Weinstein H. 1990. Transfusion-associated graft-versus-host disease. N. Engl. J. Med. 323:315-21
37. 37. Frassoni F, Fagioli F, Sessarego M, et al. 1992. The effect of donor leucocyte infusion in patients with leukemia following allogeneic bone marrow transplantation. Exp. Hematol. 20:712
38. 38. Arcese W, Goldman J, D'Arcangelo E, et al. 1993. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 82:3211-19
39. 39. Radich J, Sanders J, Buckner C, et al. 1993. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial tranplant with total-body irradiation-containing regimens. J. Clin. Oncol. 11:304-13
40. 40. Higano C, Raskind W, Singer J. 1992. Use of alpha Interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80: 1437-42
41. 41. Porter D, Collins R, Drobyski W, et al. 1997. Long-term follow-up of 55 patients who achieved complete remission (CR) after donor leukocyte infusions (DLI) for relapse after allogeneic bone marrow transplantation (BMT). Blood 90:549a
42. 42. Faber L, van Luxemburg-Heijs A, Veenhof W, et al. 1995. Generation of CD4+ cytotoxic T-lympocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 86:2821-28
43. 43. Jiang Y, Kanfer E, MacDonald D, et al. 1991. Graft versus leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transpl. 8:253-58
44. 44. Datta A, Barret A, Jiang Y, et al. 1994. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transpl. 14: 517-24
45. 45. Sosman J, Oettel K, Smith S, et al. 1990. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 75:2005-16
46. 46. Bunjes D, Theobald M, Hertenstein B, et al. 1995. Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells. Bone Marrow Transpl. 15:713-19
47. 47. Jiang Y, Cullis J, Kanfer E, et al. 1993. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transpl. 11:133-38
48. 48. Oettel K, Wesly O, Albertini M, et al. 1994. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1 - cells from the same patient. Blood 83:3390-3402
49. 49. Nimer S, Giorgi J, Gajewski J, et al. 1994. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplant 57:82-87
50. 50. Alyea E, Soiffer R, Canning C, et al. 1998. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671-80
51. 51. Giralt S, Hester J, Huh Y, et al. 1995. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86: 4337-43
52. 52. Hauch M, Gazzola M, Small T, et al. 1990. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow tranplantation for chronic myelogenous leukemia. Blood 75: 2250-62
53. 53. Reittie J, Gottlieb D, Heslop H, et al. 1989. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73: 1351-58
54. 54. Hercend T, Takvorian T, Nowill A, et al. 1986. Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 67:722-28
55. 55. Mackinnon S, Hows J, Goldman J. 1990. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 76:2037-45
56. 56. Cullis J, Barrett A, Goldman J, et al. 1994. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. Leukemia 8:165-70
57. 57. Bocchia M, Wentworth P, Southwood S, et al. 1995. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85:2680-84
58. 58. Bocchia M, Korontsvit T, Xu Q, et al. 1996. Specific human cellular immunity to bcr-abl oncogene derived peptides. Blood 87:3587-92
59. 59. Chen W, Peace D, Rovira D, et al. 1992. T-cell immunity to the joining region of p210 BCR-ABL protein. Proc. Natl. Acad. Sci USA 89:1468-72
60. 60. ten Bosch G, Joosten A, Kessler J, et al. 1996. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88:3522-27
61. 60a. Choudhury A, Gajewski JL, Liang JC, et al. 1997. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89(4):1133-42
62. 61. Guinan E, Gribben J, Boussiotis V, et al. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261-82
63. 62. Upadhyaya G, Gupta S, Sih S, et al. 1991. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J. Clin. Invest. 88:2131
64. 63. Kloosterman T, Tielemans M, Martens A, et al. 1994. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia. Bone Marrow Transpl. 14:15-22
65. 64. Kloosterman T, Marten A, van Bekkum D, et al. 1994. Graft-versus-leukemia in rate MHC-mismatched bone marrow transplantation is merely an allogeneic effect. Bone Marrow Transpl. 15:583-90
66. 65. Shapiro R, McClain K, Frizzera G, et al. 1988. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71: 1234-43
67. 66. Porter D, Orloff G, Antin J. 1994. Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant. Sci. 4:11-15
68. 67. Papadopoulos E, Ladanyi M, Emanuel D, et al. 1994. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1185-91
69. 68. Roskrow M, Suzuki N, Gan Y, et al. 1998. Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91:2925-34
70. 69. Reusser P, Riddel S, Meyers J, Greenberg P. 1991. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373-80
71. 70. Riddell S, Watanabe K, Goodrich J, et al. 1992. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 257: 238-41
72. 71. Walter E, Greenberg P, Gilbert M, et al. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-44
73. 72. Hromas R, Cornetta K, Srour E. 1995. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 84:1690-91
74. 73. Pan L, Delmonte J, Jalonen C, Ferrara L. 1995. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422-29
75. 74. Mackinnon S, Papadopoulos E, Carabasi M, et al. 1995. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-68
76. 75. Servida P, Rossini S, Traversari C, et al. 1993. Gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in a patient affected by EBV-induced lymphoma. Blood 82:214a
77. 76. Porter D, Connors J, Doyle B, et al. 1997. Donor leukocyte infusions as primary allogeneic adoptive immunotherapy for patients with malignancies. Blood 90:549a
78. 77. Khouri I, Keating M, Przepiorka D, et al. 1996. Engraftment and induction of GVL with fludarabine (FAMP)-based nonablative preparative regimen in patients with chronic lymphocytic leukemia (CLL) and lymphoma. Blood 88:301a
79. 78. Giralt S, Gajewski J, Khouri I, et al. 1997. Induction of graft-vs-leukemia (GVL) as primary treatment of chronic myelogenous leukemia (CML). Blood 90:418a
80. 79. Giralt S, Estey E, Albitar M, et al. 1997. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-36
81. 80. Slavin S, Nagler A, Naparstek E, et al. 1998. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventianal bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756-63